Cargando…
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for mana...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161526/ https://www.ncbi.nlm.nih.gov/pubmed/25228819 http://dx.doi.org/10.2147/CMAR.S68102 |
_version_ | 1782334576851419136 |
---|---|
author | Affronti, Mary Lou Bubalo, Joseph |
author_facet | Affronti, Mary Lou Bubalo, Joseph |
author_sort | Affronti, Mary Lou |
collection | PubMed |
description | Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for management of CINV in patients receiving multiple-day chemotherapy regimens. Serotonin (5-HT(3)) receptor antagonists are a mainstay in preventing CINV, and palonosetron, given its longer half-life and duration of action relative to other 5-HT(3) receptor antagonists, may be a useful option for managing CINV in multiple-day chemotherapy. Here we provide an overview of CINV and CINV treatment options, with a focus on palonosetron. We describe existing challenges in managing CINV, and discuss two patients receiving multiple-day chemotherapy, in whom CINV was managed successfully with palonosetron. |
format | Online Article Text |
id | pubmed-4161526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41615262014-09-16 Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy Affronti, Mary Lou Bubalo, Joseph Cancer Manag Res Review Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for management of CINV in patients receiving multiple-day chemotherapy regimens. Serotonin (5-HT(3)) receptor antagonists are a mainstay in preventing CINV, and palonosetron, given its longer half-life and duration of action relative to other 5-HT(3) receptor antagonists, may be a useful option for managing CINV in multiple-day chemotherapy. Here we provide an overview of CINV and CINV treatment options, with a focus on palonosetron. We describe existing challenges in managing CINV, and discuss two patients receiving multiple-day chemotherapy, in whom CINV was managed successfully with palonosetron. Dove Medical Press 2014-09-05 /pmc/articles/PMC4161526/ /pubmed/25228819 http://dx.doi.org/10.2147/CMAR.S68102 Text en © 2014 Affronti and Bubalo. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Affronti, Mary Lou Bubalo, Joseph Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy |
title | Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy |
title_full | Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy |
title_fullStr | Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy |
title_full_unstemmed | Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy |
title_short | Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy |
title_sort | palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161526/ https://www.ncbi.nlm.nih.gov/pubmed/25228819 http://dx.doi.org/10.2147/CMAR.S68102 |
work_keys_str_mv | AT affrontimarylou palonosetroninthemanagementofchemotherapyinducednauseaandvomitinginpatientsreceivingmultipledaychemotherapy AT bubalojoseph palonosetroninthemanagementofchemotherapyinducednauseaandvomitinginpatientsreceivingmultipledaychemotherapy |